Singapore markets closed

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7299+0.0149 (+2.08%)
At close: 04:00PM EST
0.7249 -0.00 (-0.69%)
After hours: 07:32PM EST

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500

Full-time employees164

Key executives

NameTitlePayExercisedYear born
Mr. Cezar Andrei Floroiu M.B.A.CEO, President & Director674.98kN/A1973
Dr. Sean N. Tucker Ph.D.Senior VP & Chief Scientific Officer481.52kN/A1969
Dr. James F. Cummings M.D.Chief Medical Officer526.96kN/A1967
Mr. Phillip Eric LeeCFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1988
Dr. Raymond D. Stapleton Jr., Ph.D.Chief Technology OfficerN/AN/A1971
Mr. Edward B. BergSenior VP & General CounselN/AN/A1965
Ms. Sarah Caravalho KhanVP & Head of Human ResourcesN/AN/AN/A
Ms. Shaily Jaini GargSenior Vice President of Clinical Development & Project ManagementN/AN/AN/A
Mr. Brant BiehnSenior Vice President of Business OperationsN/AN/AN/A
Dr. Rajesh Kapoor Ph.D.Senior Vice President of QualityN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Corporate governance

Vaxart, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.